Skip to main content

Advertisement

Table 2 Demographic data of study subjects used in tumour necrosis factor-α and lymphotoxin α1β2 stimulation experiments

From: Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis

  Healthy control subjects (n = 5) Individuals with RA risk (n = 5) Patients with early RAa (n = 5)
Passages P4–P6 P5–P8 P6–P7
Female sex, n (%) 5 (100) 5 (100) 4 (80)
Median age, years (IQR) 28 (26–40) 51 (49–57) 35 (28–58)
IgM-RF-positive, n (%) 0 (0) 4 (80) 3 (60)
IgM-RF level, kU/L, median (IQR) 3 (1–42) 6 (3–288)
ACPA-positive, n (%) 0 (0) 4 (80) 4 (80)
ACPA level, kAU/L, median (IQR) 47 (16–343) 54 (22–1563)
IgM-RF and ACPA both positive, n (%) 0 (0) 0 (0) 2 (40)
DAS28, median (IQR) 3.9 (3–7)
CRP, mg/L, median (IQR) 0.4 (0.3–2.7) 3.2 (1.9–4.4) 3 (0.9–100.4)
  1. Abbreviations: ACPA anti-citrullinated protein antibodies, kAU/L kilo arbitrary Unit/L, CRP C-reactive protein, DAS28 disease activity score in 28 joints, IgM-RF immunoglobulin M-rheumatoid factor, kU/L kilo Unit/L, RA rheumatoid arthritis
  2. a Patients with early RA: naïve for disease-modifying anti-rheumatic drugs and biologics with a disease duration (defined by arthritis in any joint) less than 1 year